AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Pharmaphorum

Published November 13, 2026 · Updated November 14, 2026

Neurosterix' $105m round leads the week's biotech financings - pharmaphorum

Read the full story at Pharmaphorum

Delix Therapeutics – which is developing psychedelic -derived therapies for psychiatric and neurological conditions known as 'neuroplastogens.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech